Advertisement
UK markets close in 5 hours 32 minutes

  • FTSE 100

    7,870.64
    +22.65 (+0.29%)
     

  • FTSE 250

    19,412.41
    +72.27 (+0.37%)
     

  • AIM

    744.46
    +1.34 (+0.18%)
     

  • GBP/EUR

    1.1687
    +0.0020 (+0.17%)
     

  • GBP/USD

    1.2471
    +0.0015 (+0.12%)
     

  • Bitcoin GBP

    49,387.45
    -1,425.18 (-2.80%)
     

  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     

  • S&P 500

    5,022.21
    -29.20 (-0.58%)
     

  • DOW

    37,753.31
    -45.66 (-0.12%)
     

  • CRUDE OIL

    81.99
    -0.70 (-0.85%)
     

  • GOLD FUTURES

    2,394.70
    +6.30 (+0.26%)
     

  • NIKKEI 225

    38,079.70
    +117.90 (+0.31%)
     

  • HANG SENG

    16,385.87
    +134.03 (+0.82%)
     

  • DAX

    17,773.49
    +3.47 (+0.02%)
     

  • CAC 40

    8,014.47
    +32.96 (+0.41%)
     
Money:

Best mortgage deals of the week

As possibility of multiple interest rate cuts dwindle here's what banks and building societies are offering

CVS Health's Schnuck Pharmacy Buyout to Widen Specialty Arm

Zacks Equity Research
·3-min read

CVS Health CVS has been expanding steadily on an inorganic basis. Following the company’s partnership deals in kidney care market earlier this month, its subsidiary, CVS Pharmacy, Inc. has entered into a definitive acquisition agreement to expand in the growing field of specialty pharmacy.

Per the agreement, the company will acquire the retail and specialty pharmacy businesses of Schnuck Markets Inc., a third-generation, family-owned grocery and pharmacy retailer. Under the terms of the deal, CVS Pharmacy along with its subsidiaries will acquire and operate 99 pharmacy locations of Schnuck pharmacies and will rebrand them as CVS Pharmacy. Further, the company will also acquire the prescription files from 11 Schnucks pharmacies and transfer them to nearby CVS Pharmacy locations.

Financial terms of the deal, however, have been kept under wrap.The deal is expected to be completed by the end of second-quarter 2020, subject to customary closing conditions.

How Far is the Deal Strategic?

Schnuck’s pharmacy network is spread across Missouri, Illinois, Indiana, Wisconsin and Iowa. Post integration, CVS Health will leverage on this widespread network to strengthen its foothold in the Midwest region of the United States. This deal also remains in line with CVS Health's strategic priority to ‘Be Local’. With the acquisition, CVS Health will be able to open its Pharmacy locations within Schnucks stores, thereby increasing access to customers.

Further, the company believes that CVS Pharmacy's advanced pharmacy services and clinical skill will improve health outcome for Schnucks customers. This acquisition will also provide CVS Health with a capital-efficient way to expand into key areas.

ADVERTISEMENT

Also, the acquisition aligns with CVS Health’s key strategy to exit tobacco. In this regard, the company was the first and only major retail pharmacy to bar tobacco from its business back in 2014. Notably, Schnucks stores became tobacco free from January 2020.

Specialty Pharmacy Industry Prospect and CVS Health

Going by a Pharmacy times data, since 2011, specialty spending has increased by 73% and specialty pharmacy is projected to grow to $500 billion by 2020.

With management emphasizing that CVS Health’s specialty business remains a top priority for its customers, we believe it is well positioned to tap this opportunity based on the broad, differentiated offerings.

Going forward, management expects drug price inflation, new product launch, higher utilization and new PBM clients to fuel growth. The acquisition of Schnuck pharmacies, post its completion, is expected to act as an added impetus to this business’ growth.

Share Price Performance

Over the past six months, CVS Health has outperformed its industry. The stock has lost 2%, narrower than the 6% decline of the industry.

Zacks Rank & Key Picks

CVS Health currently carries a Zacks Rank #3 (Hold).

Some better-ranked stocks from the broader medical space are ResMed Inc. RMD, Medtronic plc MDT and Hill-Rom Holdings, Inc. HRC.

ResMed has a projected long-term earnings growth rate of 14.5%. It currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Medtronic’s long-term earnings growth rate is estimated at 7.4%. The company presently carries a Zacks Rank #2.

Hill-Rom’s long-term earnings growth rate is estimated at 11.1%. It currently carries a Zacks Rank #2.

The Hottest Tech Mega-Trend of All

Last year, it generated $24 billion in global revenues. By 2020, it's predicted to blast through the roof to $77.6 billion. Famed investor Mark Cuban says it will produce "the world's first trillionaires," but that should still leave plenty of money for regular investors who make the right trades early.

See Zacks' 3 Best Stocks to Play This Trend >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Medtronic PLC (MDT) : Free Stock Analysis Report
 
CVS Health Corporation (CVS) : Free Stock Analysis Report
 
ResMed Inc. (RMD) : Free Stock Analysis Report
 
Hill-Rom Holdings, Inc. (HRC) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research